Gunda Daniel W, Kilonzo Semvua B, Kamugisha Erasmus, Rauya Engelbert Z, Mpondo Bonaventura C
Department of Medicine, Weill Bugando School of Medicine, 1464, Mwanza, Tanzania.
Department of Biochemistry and Molecular Biology, Weill Bugando School of Medicine, 1464, Mwanza, Tanzania.
BMC Res Notes. 2017 Jun 8;10(1):197. doi: 10.1186/s13104-017-2521-0.
Highly Active Antiretroviral therapy (HAART) reverses the effect of Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS) by durably suppressing viral replication. This allows CD4 gain to levels that are adequate enough to restore the body's capability to fight against opportunistic infections (OIs). Patients with poor immune recovery have been shown to have higher risk of developing both AIDS and non AIDS related clinical events. This study aimed at assessing the proportions and risk factors of poor immune recovery in adult HIV-infected patients on 48 months of HAART attending care and treatment center (CTC) in northwestern Tanzania.
A retrospective analysis of adult HIV patients' data attending CTC at Sekou Toure hospital and who initiated HAART between February 2004 and January 2008 was done. Poor immune recovery was defined as a CD4 count less than 350 cells/µl on follow up as used in other studies.
A total of 734 patients were included in the study. In this study 50.25% of patients attending CTC at Sekou Toure hospital were found to have poor immune recovery. The risk of developing inadequate immune recovery was independently associated with male gender, age older than 50 years, low baseline CD4 counts, and advanced World Health Organization (WHO) clinical stage.
Poor immune recovery is prevalent among adult HIV patients attending CTC at Sekou Toure hospital in Northwestern part of Tanzania and opportunistic infections are common in this sub group of patients. Clinicians in resource limited countries need to identify these patients timely and plan them for targeted viral assessment and close clinical follow up to improve their long term clinical outcome.
高效抗逆转录病毒疗法(HAART)通过持久抑制病毒复制来逆转人类免疫缺陷病毒/获得性免疫缺陷综合征(HIV/AIDS)的影响。这使得CD4细胞数量增加到足以恢复身体抵抗机会性感染(OIs)能力的水平。免疫恢复不佳的患者发生与艾滋病相关和非艾滋病相关临床事件的风险更高。本研究旨在评估在坦桑尼亚西北部接受治疗和关怀中心(CTC)48个月HAART治疗的成年HIV感染患者中免疫恢复不佳的比例及危险因素。
对2004年2月至2008年1月在塞古·杜尔医院CTC开始接受HAART治疗的成年HIV患者的数据进行回顾性分析。如其他研究中所采用的,免疫恢复不佳定义为随访时CD4细胞计数低于350个/微升。
共有734名患者纳入本研究。在本研究中,发现塞古·杜尔医院CTC的患者中有50.25%免疫恢复不佳。免疫恢复不足的风险与男性、年龄大于50岁、基线CD4细胞计数低以及世界卫生组织(WHO)临床分期晚期独立相关。
在坦桑尼亚西北部塞古·杜尔医院CTC接受治疗的成年HIV患者中,免疫恢复不佳很普遍,并且机会性感染在该亚组患者中很常见。资源有限国家的临床医生需要及时识别这些患者,并为他们制定针对性的病毒评估和密切临床随访计划,以改善其长期临床结局。